RedHill Biopharma Ltd. (RDHL) income statement
RDHLNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.78MP/E –Yield –
RedHill Biopharma Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -2776.9%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.34
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 20.2%
Valuation
- P/E ratio
- –
- Price to sales
- 6.23
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?